A controversial gene therapy technique has produced human embryos free of defective maternal genes responsible for rare, debilitating diseases. "This is good, solid work; the real advance is to perform the procedure in human cells," says biologist Keith Latham of Temple’s School of Medicine. However, he expressed caution about the chances of the Food and Drug Administration (FDA) approving clinical trials of the procedure.